**Table 1. Characteristics of the case and control patients with liver cirrhosis**

|  |  |  |  |
| --- | --- | --- | --- |
| **Characteristics** | **Cases (n = 114)** | **Controls (n = 228)** | **P value** |
| Male sex, n (%) | 59 (51.8) | 116 (50.9) | 0.879 |
| Age, years | 59 (51; 65) | 58 (52; 63) | 0.698 |
| Causes of liver cirrhosis, n (%) | | | |
| Alcohol abuse | 28 (24.6) | 58 (25.4) | 0.861 |
| CVH | 42 (36.8) | 82 (36) | 0.874 |
| CVH and alcohol abuse | 16 (14) | 29 (12.7) | 0.735 |
| NAFLD | 16 (14) | 35 (15.4) | 0.748 |
| Primary biliary cholangitis | 9 (7.9) | 18 (7.9) | 1.000 |
| Autoimmune hepatitis | 3 (2.6) | 6 (2.6) | 1.000 |
| LC Child-Pugh class, n (%) | | | |
| А | 23 (20.2) | 46 (20.2) | 1.000 |
| B | 62 (54.4) | 117 (51.3) | 0.593 |
| С | 29 (25.4) | 65 (28.5) | 0.549 |
| Ascites, n (%) | 88 (77.2) | 129 (56.6) | < 0.001 |
| HE, n (%) | 45 (39.5) | 69 (30.3) | 0.089 |
| GEV, n (%) | 105 (92.1) | 212 (93) | 0.769 |
| History of GEV-associated bleeding, n (%) | 36 (31.6) | 34 (14.9) | < 0.001 |
| Spleen length (at sonography), cm | 16.2 (14.7; 18.2) | 14.9 (13.4; 16.1) | < 0.001 |
| PV diameter (at sonography), mm | 14 (12.8; 16) | 12.5 (11.3; 13.6) | < 0.001 |
| Hemoglobin, g/L | 119 (99; 130) | 120 (107; 133) | 0.244 |
| WBC count, × 109/L | 4.1 (3.1; 5.3) | 4.5 (3.2; 5.9) | 0.104 |
| Neutrophils, × 109/L | 2.35 (1.81; 3.54) | 2.6 (1.7; 3.74) | 0.293 |
| Lymphocytes, × 109/L | 0.98 (0.64; 1.37) | 1.21 (0.84; 1.75) | < 0.001 |
| NLR | 2.48 (1.93; 3.62) | 2.07 (1.47; 3.04) | < 0.001 |
| Platelets, n (%) | 88 (61; 131) | 85 (61; 130) | 0.768 |
| < 50 × 109/L | 18 (15.8) | 31 (13.6) | 0.586 |
| ≥ 50 – < 100 × 109/L | 47 (41.2) | 105 (46.1) | 0.398 |
| ≥ 100 – < 150 × 109/L | 36 (31.6) | 56 (24.5) | 0.168 |
| ≥ 150 × 109/L | 13 (11.4) | 36 (15.8) | 0.276 |
| Total protein, g/L | 69 (64; 75) | 70 (65; 76) | 0.260 |
| Albumin, g/L | 32 (27; 36) | 30 (26; 34.7) | 0.019 |
| Total bilirubin, mg/dL | 1.8 (1.3; 2.9) | 2.4 (1.5; 3.8) | 0.008 |
| INR | 1.29 (1.16; 1.47) | 1.24 (1.14; 1.39) | 0.032 |
| Fibrinogen, g/L | 2.5 (2; 3.1) | 2.5 (2; 3.1) | 0.745 |

CVH, chronic viral hepatitis; GEV, gastroesophageal varices; HE, hepatic encephalopathy; INR, international normalized ratio; LC, liver cirrhosis; NAFLD, non-alcoholic fatty liver disease; NLR, neutrophil/lymphocyte ratio; PV, portal vein; WBC, white blood cell

The values are given as absolute patient numbers and proportions of the total – n (%), or as median and interquartile range (25th; 75th percentiles)

**Table 2. Characteristics of the case and control patients with liver cirrhosis with the subgroups based on the presence or absence of thrombocytopenia**

|  |  |  |  |  |  |  |
| --- | --- | --- | --- | --- | --- | --- |
| **Characteristics** | **Cases (n = 114)** | | **P value** | **Controls (n = 228)** | | **P value** |
| **Thrombocytopenia (n = 101)** | **No thrombocytopenia (n = 13)** | **Thrombocytopenia (n = 192)** | **No thrombocytopenia (n = 36)** |
| Male sex, n (%) | 52 (51.5) | 7 (54) | 0.873 | 93 (48.4) | 23 (63.9) | 0.089 |
| Age, years | 59 (50; 66) | 60 (57; 66) | 0.672 | 59 (52; 63) | 57 (46; 63) | 0.349 |
| Alcohol etiology, n (%) | 35 (34.6) | 9 (69) | 0.016 | 65 (33.8) | 22 (61) | 0.003 |
| Ascites, n (%) | 76 (75.2) | 12 (92) | 0.168 | 103 (53.6) | 26 (72) | 0.040 |
| HE, n (%) | 38 (37.6) | 7 (54) | 0.261 | 58 (30.2) | 11 (31) | 0.967 |
| GEV, n (%) | 94 (93.1) | 11 (85) | 0.288 | 178 (92.7) | 34 (95) | 0.709 |
| History of GEV-associated bleeding, n (%) | 34 (33.7) | 2 (15) | 0.183 | 31 (16.1) | 3 (8.3) | 0.228 |
| Spleen length (at sonography), cm | 16.2 (14.8; 18.7) | 15.3 (13.4; 17.7)\* | 0.196 | 14.9 (13.7; 16.4) | 13.6 (12.3; 15.5) | 0.007 |
| PV diameter (at sonography), mm | 14 (12.7; 15.8) | 15 (13; 16.1)\* | 0.273 | 12.5 (11.2; 13.3) | 12.7 (11.4; 14) | 0.513 |
| Hemoglobin, g/L | 120 (100; 130) | 114 (82; 127) | 0.102 | 119 (107; 133) | 128 (102; 137) | 0.169 |
| WBC count, × 109/L | 3.9 (2.9; 5.2) | 6 (3.8; 9.1) | 0.031 | 4.2 (3; 5.3) | 7.6 (6.1; 14.3) | < 0.001 |
| Neutrophils, × 109/L | 2.3 (1.78; 3.17) | 3.61 (2.08; 7.11) | 0.016 | 2.27 (1.62; 3.2) | 4.98 (3.5; 9.18) | < 0.001 |
| Lymphocytes, × 109/L | 0.92 (0.62; 1.25) | 1.76 (1.11; 2) | < 0.001 | 1.15 (0.81; 1.57) | 2.1 (1.51; 2.6) | < 0.001 |
| NLR | 2.45 (1.96; 3.48) | 2.55 (1.73; 3.89) | 0.538 | 2.03 (1.44; 2.99) | 2.66 (1.77; 4.49) | 0.012 |
| Total protein, g/L | 68.5 (63.8; 74.2) | 73 (66.6; 80.2) | 0.372 | 70 (65; 75) | 68.4 (64.3; 77) | 0.285 |
| Albumin, g/L | 32 (27; 35.8) | 32.1 (26.5; 37) | 0.781 | 30 (26; 34.9) | 31 (25.3; 34.8) | 0.604 |
| Total bilirubin, mg/dL | 1.7 (1.3; 2.9) | 2.4 (1.3; 3.5) | 0.384 | 2.3 (1.5; 3.7) | 3 (1.6; 6.2) | 0.178 |
| INR | 1.3 (1.16; 1.49) | 1.18 (1.16; 1.29) | 0.436 | 1.24 (1.13; 1.4) | 1.26 (1.12; 1.39) | 0.790 |
| Fibrinogen, g/L | 2.4 (1.9; 3) | 3.2 (2.6; 4) | 0.029 | 2.4 (1.9; 3) | 3.1 (2.35; 3.88) | 0.032 |
| Newly diagnosed malignancies, n (%) | 16 (15.8) | 8 (62)\* | < 0.001 | 11 (5.7) | 5 (13.9) | 0.079 |
| HCC | 15 (14.8) | 6 (46)\* | 0.007 | 9 (4.7) | 4 (11.1) | 0.128 |
| Non-HCC | 1 (1) | 2 (15) | 0.003 | 2 (1) | 1 (2.8) | 0.402 |
| CMPD | 1 (1) | – |  | – | – |  |

CMPD, chronic myeloproliferative disorder; GEV, gastroesophageal varices; HCC, hepatocellular carcinoma; HE, hepatic encephalopathy; INR, international normalized ratio; NLR, neutrophil/lymphocyte ratio; PV, portal vein; WBC, white blood cell count

The values are given as absolute patient numbers and proportions of the total – n (%), or as median and interquartile range (25th; 75th percentiles)

\* р < 0.05 for the difference with the patient subgroup without PVT

**Table 3. Logistic regression models for the outcome “platelet count ≥ 150 × 109/L” in the case and control patients**

|  |  |  |  |  |  |
| --- | --- | --- | --- | --- | --- |
| **Variable** | **Coefficient B** | **OR** | **95% CI** | **P value** | **Wald test** |
| The case model | | | | | |
| Malignant tumors | 3.468 | 32.061 | 5.059–203.191 | < 0.001 | 13.548 |
| Hemoglobin, g/L | -0.037 | 0.964 | 0.934–0.995 | 0.024 | 5.100 |
| Albumin, g/L | 0.174 | 1.190 | 1.031–1.374 | 0.017 | 5.684 |
| WBC, × 109/L | 0.227 | 1.254 | 1.057–1.448 | 0.009 | 6.761 |
| The control model | | | | | |
| Neutrophils, × 109/л | 0.355 | 1.427 | 1.238–1.644 | < 0.001 | 24.084 |
| Spleen length (at sonography), cm | -0.204 | 0.816 | 0.676–0.984 | 0.033 | 4.528 |

CI, confidence interval; OR, odds ratio; WBC, white blood cell count